NCT03120676View on ClinicalTrials.gov

Study of Atezolizumab in Relapsed or Refractory Hodgkin Lymphoma

PHASE2TerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

April 14, 2017

Primary Completion Date

November 12, 2018

Study Completion Date

November 12, 2018

Conditions
Hodgkin Lymphoma
Interventions
DRUG

Atezolizumab

All patients will receive atezolizumab 1200 mg via IV infusion on D1 of each 21-day cycle.

Trial Locations (6)

10065

Memorial Sloan Kettering Cancer Center, New York

10604

Memorial Sloan Kettering Westchester, Harrison

11570

Memorial Sloan Kettering Rockville Centre, Rockville Centre

11725

Memorial Sloan Kettering Commack, Commack

07920

Memorial Sloan Kettering Basking Ridge, Basking Ridge

07748

Memorial Sloan Kettering Monmouth, Middletown

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT03120676 - Study of Atezolizumab in Relapsed or Refractory Hodgkin Lymphoma | Biotech Hunter | Biotech Hunter